![XiuGui Chen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
XiuGui Chen
Directeur Technique/Scientifique/R&D chez TYK Medicines, Inc.
Postes actifs de XiuGui Chen
Sociétés | Poste | Début | Fin |
---|---|---|---|
TYK Medicines, Inc.
![]() TYK Medicines, Inc. Pharmaceuticals: MajorHealth Technology TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the business of research, development and commercialization of pharmaceutical products and differentiated targeted therapies to address unmet medical needs in cancer treatment. The company was founded by Wu Yusheng on November 2, 2017 and is headquartered in Huzhou, China. | Directeur Technique/Scientifique/R&D | 01/08/2018 | - |
Historique de carrière de XiuGui Chen
Anciens postes connus de XiuGui Chen
Sociétés | Poste | Début | Fin |
---|---|---|---|
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
![]() Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Directeur Technique/Scientifique/R&D | - | - |
Formation de XiuGui Chen
Shanghai University | Doctorate Degree |
Statistiques
Internationale
Chine | 4 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
![]() Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Health Technology |
TYK Medicines, Inc.
![]() TYK Medicines, Inc. Pharmaceuticals: MajorHealth Technology TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the business of research, development and commercialization of pharmaceutical products and differentiated targeted therapies to address unmet medical needs in cancer treatment. The company was founded by Wu Yusheng on November 2, 2017 and is headquartered in Huzhou, China. | Health Technology |
- Bourse
- Insiders
- XiuGui Chen
- Expérience